Pharming Group (NASDAQ:PHAR) Short Interest Down 20.4% in November

Pharming Group (NASDAQ:PHAR) was the recipient of a significant decrease in short interest in the month of November. As of November 30th, there was short interest totalling 20,300 shares, a decrease of 20.4% from the November 15th total of 25,500 shares. Based on an average trading volume of 6,900 shares, the days-to-cover ratio is currently 2.9 days.

Pharming Group Price Performance

Shares of PHAR stock traded down $0.34 during midday trading on Friday, reaching $8.98. 2,978 shares of the company were exchanged, compared to its average volume of 5,220. The company’s 50 day moving average price is $8.27 and its two-hundred day moving average price is $8.15. The company has a market cap of $609.31 million, a P/E ratio of -34.55 and a beta of 0.05. Pharming Group has a 12 month low of $6.65 and a 12 month high of $13.20. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in Pharming Group (NASDAQ:PHAR) by 75.4% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 41,110 shares of the company’s stock after buying an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.06% of Pharming Group worth $339,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on PHAR. HC Wainwright restated a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a research report on Wednesday. Jefferies Financial Group started coverage on shares of Pharming Group in a research note on Monday, December 9th. They set a “buy” rating and a $14.00 target price for the company. Finally, Oppenheimer cut their price target on Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, October 28th.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.